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Saposin B derives from the multi-functional precursor, prosaposin, and functions as an activity enhancer for
several glycosphingolipid (GSL) hydrolases. Mutations in saposin B present in humans with phenotypes
resembling metachromatic leukodystrophy. To gain insight into saposin B’s physiological functions, a
speciﬁc deﬁciency was created in mice by a knock-in mutation of an essential cysteine in exon 7 of the pro-
saposin locus. No saposin B protein was detected in the homozygotes (B2/2) mice, whereas prosaposin,
and saposins A, C and D were at normal levels. B2/2 mice exhibited slowly progressive neuromotor deterio-
ration and minor head tremor by 15 months. Excess hydroxy and non-hydroxy fatty acid sulfatide levels were
present in brain and kidney. Alcian blue positive (sulfatide) storage cells were found in the brain, spinal cord
and kidney. Ultrastructural analyses showed lamellar inclusion material in the kidney, sciatic nerve, brain and
spinal cord tissues. Lactosylceramide (LacCer) and globotriaosylceramide (TriCer) were increased in various
tissues of B2/2 mice supporting the in vivo role of saposin B in the degradation of these lipids. CD68 posi-
tive microglial cells and activated GFAP positive astrocytes showed a proinﬂammatory response in the
brains of B2/2 mice. These ﬁndings delineate the roles of saposin B for the in vivo degradation of several
GSLs and its primary function in maintenance of CNS function. B2/2 provide a useful model for understand-
ing the contributions of this saposin to GSL metabolism and homeostasis.
INTRODUCTION
The prosaposin locus encodes in tandem four related 80
amino acid proteins, the saposins, with activation effects on
speciﬁc glycosphingolipid (GSL) hydrolases (1–4). Saposins
are proteolytically cleaved from the protein precursor, prosa-
posin, in the late endosomes and lysosomes (5–7). The stab-
ility of each saposin is maintained by three conserved
disulﬁde bridges (8). The genetic deﬁciencies of individual
saposins or prosaposin highlight their physiological import-
ance in GSL degradation (9–12). Saposin A is essential to
the metabolism of b-galactosylceramide (GalCer) (13) and
its deﬁciency leads to a late-onset form of globoid cell
leukodystrophy or Krabbe disease (14). Saposin B has lipid
transfer properties (15) and stimulates the degradation of sul-
fatide and other glycolipids (16). Saposin B deﬁciency in
humans leads to sulfatide accumulation and a metachromatic
leukodystrophy (MLD)-like disease similar to that observed
with arylsulfatase A (ASA) deﬁciency, its cognate enzyme
(17). Saposin C activates acid b-glucosidase (EC 3.2.1.45,
GCase) and deﬁciency of saposin C leads to Gaucher-like dis-
eases due to diminished GCase activity (10,18,19). Saposin D
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deﬁciency is associated with ceramide accumulation, partial
loss of Purkinje cells and impaired urinary system function
(21). This phenotype does not mimic the embryonic lethality
exhibited by mice with complete deﬁciency of acid cerami-
dase, saposin D’s cognate enzyme (22). A complete deﬁciency
of human prosaposin results in the storage of multiple GSLs
and early lethality (11,12). Targeted disruption of prosaposin
in the mouse causes a complex neurodegenerative phenotype
resulting in a severe leukodystrophy with accumulation of
GSLs in both neurons and microglial cells (23).
Saposin B facilitates partial extraction of GSLs from mem-
branes and presents sulfatides and globotriaosylceramide
(TriCer or Gb3) to ASA and a-galactosidase A, respectively,
for cleavage (24–26). The dimeric shell structure of saposin
B is critical for its binding to these hydrophobic lipids (26).
Both saposin B and C have in vitro activation effects on
GalCer-b-galactosidase, and GM1-b-galactosidase, as well
as on the b-galactosidase for hydrolysis of lactosylceramide
(LacCer) (27). Saposin B may also function as a transporter
of lipid substrates to these enzymes (15). In a recent study,
saposins A–D have been reported to promote lipid binding
to the CD1d, a molecule important for NKT cell development
(28). Saposin B is found to be most efﬁcient at facilitating this
interaction (29).
MLD is an autosomal recessive neurodegenerative lysoso-
mal disease caused by defective ASA activity (30). The
MLD variants are characterized by accumulation of sulfatides,
progressive demyelination and extensive white matter damage
(30). A few cases of MLD-like disease are caused by saposin
B deﬁciency. The saposin B defects arises from various
mutations in the saposin B domain of prosaposin that
produce substitutions for critical cysteine residues, insertions,
transversions or obliteration of a glycosylation site (31,32).
Human patients with saposin B deﬁciency have elevated sulfa-
tide levels in kidney and brain, and variable neurological phe-
notypes (31).
Deﬁciency of ASA enzymatic activity caused by targeted
disruption of ASA in mice results in diminished in vivo
enzyme activity, accumulation of sulfatide in white matter
and a neurological phenotype that manifests by 24 months
of age. There is no apparent demyelination observed in these
mice (33). One speciﬁc abnormality includes total absence
of auditory brain stem potentials. ASA2/2 mice resemble
MLD patients biochemically, however, the pathological pro-
cesses are much slower and milder.
To explore the in vivo effects and interactions of the sapo-
sins, a series of saposin mutant mice have been created with
single (14,21) or double saposin deﬁciencies (34). Here,
mice with deﬁciency of saposin B were characterized for
GSL metabolism and phenotypic development. This model
provides insight into the essential roles of saposin B in GSL
metabolism.
RESULTS
Generation and veriﬁcation of saposin B targeting
Saposin B deﬁcient mice (B2/2) were created by a knock-in
of cysteine 4 to create a phenylalanine substitution in exon 7
of the prosaposin locus that corresponds to the saposin B
domain (Fig. 1A). The mutation (Cys!Phe) was expected
to destroy one of the three essential disulﬁde bonds of
saposin B as had been the previous experience with other
saposins (14,21,34). The recombinant ES clones were
screened by PCR and conﬁrmed by Southern blot analyses
(Fig. 1B). The mutation in the ES clone was veriﬁed by
PCR and DNA sequencing. The resulting F1 heterozygous
mice were bred with Zp3-Cre transgenic mice to remove the
ﬂoxed neo in the female germline (see Materials and
Methods). The Zp3-Cre was subsequently outbred by crosses
into wild-type (WT) C57BL/6J mice and conﬁrmed by PCR
(Fig. 1C).
RT–PCR of brain RNA veriﬁed that prosaposin mRNA was
expressed at WT levels in saposin B2/2 mice (Fig. 1D).
Immunoblotting using antibodies speciﬁc to each saposin
demonstrated the absence of saposin B protein, whereas prosa-
posin and saposins A and D were expressed at WT levels in
B2/2 mice tissues (Fig. 2). Saposin C levels in B2/2 ﬁbro-
blast cells were slightly higher (1.4-fold) than those in WT.
Phenotype of saposin B2/2 mice
The onset of neurological impairment in B2/2 mice was at
12 months of age as manifested by an unsteady gait.
When suspended inverted by the tail, the B2/2 mice reﬂex-
ively grasped and tucked their hind-limbs to their body,
whereas WT mice spread their hind-limbs and remained
hanging downward (Fig. 3A). In addition, B2/2 mice exhib-
ited agitation and head tremor while standing (Fig. 3B). Ataxia
and intermittent shivering was observed by 15 months. Adult
B2/2 mice had a body weight of 86% of WT littermates and
survived up to 23 months. Male and female B2/2 mice had
normal fertility and no sex-speciﬁc differences were observed
in phenotype or biochemistry.
Neurobehavioral assessment in saposin B2/2 mice
The narrow bridges test evaluates balance and motor perform-
ance. To avoid possible sex variation, only male mice were
used in the study. B2/2 mice showed progressive increases
in latency to cross the beams and also in hind-limb slips on
5 and 12 mm square beams. At 2 months, increases in slips
reached statistical signiﬁcance on the 12 mm square beam.
A signiﬁcant increase in latency was shown by 12 months
that was consistent with the decline of motor function in
B2/2 mice at this age. By 15 months, the ability to cross
the beam was greatly diminished (Fig. 3C). On the 5 mm
square beam, 90% of the B2/2 mice at 15 months failed to
maintain their balance and fell off the beam. The tests on
the 25 mm square, and the 11 and 17 mm round beams
showed signiﬁcant increases in slips or latency to cross in
12 and 15-month-old B2/2 mice (data not shown). Loco-
motor activity in the same mice was tested for general explora-
tion and adaptation. There were no signiﬁcant differences in
locomotor activity between B2/2 and WT mice at any of
the ages tested (data not shown). Long-term potentiation
(LTP) was measured to assess hippocampal plasticity, and
no signiﬁcant differences were observed in B2/2 mice in
hippocampal LTP compared with WT at 15 month of age
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gressive decline in balance and motor coordination on the
narrow bridges test, but general exploration and hippocampal
LTP were similar to WT.
Histological and ultrastructural analyses
Hematoxylin and eosin (H&E) stained sections of
15-month-old B2/2 mice showed inclusions in a few
neurons of spinal cord, brain stem (Fig. 5) and white matter
of cerebellum (data not shown). Acoustic ganglion cells in
the inner ear also had storage inclusions (Fig. 5). Neuronal
cells in dorsal root ganglion contained foamy inclusion
material (Fig. 5). To assess the activation of macrophage/
microglial cells, anti-CD68 antibody was used to stain the sec-
tions. CD68 is an intracellular membrane glycoprotein
expressed in quiescent and activated tissue macrophages
(35). Positive CD68 staining cells were observed in spinal
cord, sciatic nerve, kidney and various regions of brain includ-
ing thalamus, cortex, cerebellum and brain stem (Fig. 6).
Liver, spleen and lung in B2/2 mice had background
levels of CD68 signal comparable to WT mice. GFAP is an
astrocyte marker and enhanced GFAP signal indicates astro-
gliosis or activated astrocytes. Using anti-GFAP antibody,
strong signals were present in the brain stem, corpus callosum,
thalamus (Fig. 6), spinal cord and cerebellum (data not shown)
of B2/2 mice relative to age-matched WT sections. Acti-
vation of microglial cells and astrocytes demonstrates proin-
ﬂammatory responses in the CNS of B2/2 mice.
In 15-month-old B2/2 mice, strong alcian blue staining
was observed in the brain stem, cortex, cerebellum, thalamus
and spinal cord, indicating the presence of acidic sulfated sub-
stances (Fig. 7A). Kidney tubules also stained positive for
alcian blue (Fig. 7A). Liver, lung, pancreas, thymus and
spleen were negative for alcian blue staining. Observable sul-
fatide accumulation began in the kidney at 7 weeks, in the
spinal cord at 12 weeks and in the brain at 24 weeks (data
not shown). To characterize the cell types containing sulfatide,
consecutive spinal cord sections were stained with alcian blue
and cell-speciﬁc markers, including: CD68, a microglial cell
marker, myelin basic protein (MBP), an oligodendrocyte
marker, and anti-NeuN antibody, a neuronal nuclei marker
(Fig. 7B). Alcian blue staining cells were in the MBP positive
region. Few CD68 stained microglia cells contained alcian
blue staining materials. Neuronal soma was free of alcian
blue, but such staining was detected on the neuronal processes.
These results provide evidence for excess acidic sulfated sub-
stances primarily in oligodendrocytes.
Ultrastructural analyses revealed large amounts of storage
material in the kidney proximal and distal tubular epithelia
Figure 1. Saposin B knock-in targeting construct and veriﬁcation. (A) Schematic map of saposin B targeting construct shows that the mutation in saposin B
(Cys!Phe) located in exon 7. Individual saposins are encoded by the exons as indicated. The mutation destroys one of three disulﬁde bridges in saposin B
that leads to a deﬁciency of the saposin B protein. The neo gene was removed by recombination on loxP sites through cross breeding of saposin B heterozygotes
and Zp3-Cre transgenic mice. B, BamH I; Bg, Bgl II; H, Hind III; E, EcoRI ;X ,Xba I; P, Pvu II; C, Cla I; K, Kpn I; Xh, Xho I.  ¼mutation site. (B) Correct
targeting of ES cells was conﬁrmed by Southern blot using 50 probe. The ES cell clone DNAs were digested with BamH I/Bgl II. (C) PCR genotyping of saposin
B mice before and after Cre recombination using primers B-F and B-R across the loxP sites. (D) RT–PCR of brain RNA from WT and B2/2 mice showed
normal level of prosaposin RNA in B2/2 mice. RT, reverse transcription. No RT, RT reaction without reverse transcriptase as a negative control. The GAPDH
was an internal control.
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The storage materials were heterogeneous aggregates of
variable sized granular material and multivesicular bodies.
Oligodendrocytes in brain stem, next to myelin process,
were ﬁlled with heterogeneous membranous material sur-
rounding more electron lucent material (Fig. 8D). Storage
materials in oligodendrocytes and neuronal processes also
were found in other regions of brain and spinal cord.
Neurons in B2/2 brain stem and spinal cord contained a
few scattered inclusion bodies (Fig. 8E). The Schwann cells
in sciatic nerve had inclusion bodies composed of large vacu-
oles mixed with electron dense amorphous material (Fig. 8F).
Myelin layering was normal in B2/2 mice (Fig. 8F). Consist-
ent with these results, the level of MBP, a component of
myelin sheath, was not altered in B2/2 mice as assessed
by immunoblotting (data not shown). This result suggests
that sulfatide accumulation has no apparent adverse effects
on myelin sheath integrity.
GSL analyses
Resolution of lipids on thin-layer chromatography (TLC)
showed a slight increase of LacCer in B2/2 liver relative
to the elevated levels in the prosaposin knock-out (PS2/2)
mice (Fig. 9A). Elevated sulfatide was detected in the
kidney, lung (Fig. 9B) and brain (not shown). A moderate
increase of TriCer or Gb3 was observed in the kidney
(Fig. 9B). The cerebral cortex displayed levels of gangliosides
(GM1, GM2, GM3, GD 1a and 1b, GT1b) comparable to WT
controls (Fig. 9C). In addition, increased amounts of sulfatide
were in the urine of B2/2 mice (data not shown).
The composition of accumulated sulfatide was analyzed by
Electrospray ionization tandem mass spectrometry (ESI/MS).
Increases in non-hydroxy fatty acid (NFA) and hydroxyl
fatty acid (HFA) sulfatides were detected in kidney and
brain of B2/2 mice. At 48 weeks, B2/2 mice kidney con-
tained 5.1- and 2.3-fold increases of C20–C24 NFA and HFA
sulfatide, respectively (Fig. 10A). To reduce background
levels of sulfatide in white matter, the cerebral cortex and hip-
pocampus were dissected and analyzed for sulfatide accumu-
lation (Fig. 10B). Most of the HFA sulfatides (C18–C24)
showed marked increases. At 14.5 months of age the major
accumulated NFA sulfatide species were C18 and C24 in the
cortex and hippocampus. Overall, 2-fold increases in total
HFA and NFA sulfatides were present in B2/2 mouse
brain samples. In the brain, C18 sulfatide was the major
species affected, whereas long fatty acid acyl chain sulfatides
predominated in the kidney. In contrast to the kidney, the NFA
sulfatide levels in brain were higher than HFA sulfatide. Cer-
amide levels were unchanged in the brain and kidney of
B2/2 mice.
DISCUSSION
Genetic deﬁciencies of individual saposins (A, B, C and D)
lead to lysosomal storage diseases (9,11,14,17,21). About 10
cases of saposin B deﬁciency states have been described in
humans (31,32). To understand the in vivo functions of
saposin B, mice were generated by introducing a point
mutation into the saposin B domain of the prosaposin gene.
This mutation disrupted a conserved disulﬁde bond that led
to an unstable/undetectable saposin B protein, but preserved
prosaposin, and saposin A, C and D processing and function.
This strategy was also used to generate the saposin A, D and
CD deﬁcient mice (14,21,34), and facilitated the in vivo
assessment of isolated saposin deﬁciency states in various
organs.
The B2/2 mice mimicked the biochemistry and phenotype
of the human disease. Similar to human patients (31), B2/2
mice developed neurological impairment including ataxia,
head tremor and impaired neuromotor coordination. The
early onset severe and late onset variants of saposin B
deﬁciency have phenotypes resembling MLD with normal
ASA activity (31). Furthermore, the point substitution and
aberrant splicing mutations described in humans lead to a
deﬁciency of mature saposin B with no effect on precursor
transport and processing (36), but manifest excesses of Gb3
(TriCer), LacCer and GM3 in cultured ﬁbroblasts from
affected patients (31,37). Urine from these patients also
contains elevated levels of sulfatide, Gb3 and digalactosylcer-
amide (37). These ﬁndings are similar to those of the B2/2
mouse. Electron microscopic ﬁndings in B2/2 mice
showed similar inclusion bodies as reported in humans (32).
However, the disease course in mice was more slowly pro-
gressive than humans, suggesting substrate turnover differ-
ences between mice and humans as has been observed in
Gaucher disease point mutation models in mice (38).
The predominant function of saposin B was in sulfatide
degradation. However, the accumulation of LacCer and Gb3
(10–20%) in B2/2 mice demonstrated that saposin B
also is involved in degradation of these lipids. This ﬁnding
indicates that saposin B does have in vivo functions in assist-
ing a-galactosidase A and the b-galactosidase(s) involved in
Gb3 and LacCer degradation, respectively, but these roles
are minor in most tissues. LacCer is increased .2-fold and
is the major lipid accumulated in the PS2/2 mice (23), and
is likely a major contributor to the pathogenesis of the prosa-
posin deﬁciency. The effects of the increases in LacCer and
Figure 2. Saposin proteins in representative tissues of saposin B2/2 mice.
No saposin B was detected, whereas prosaposin was at WT levels in liver
using anti-mouse saposin B antibody. Saposins A and D were at normal
levels in B2/2 brains detected with anti-mouse saposin A or saposin D anti-
bodies, respectively. Using anti-mouse saposin C antibody, saposin C in
B2/2 ﬁbroblast cells was slightly increased compared with WT controls.
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suggested by the increases in Gb3 in the Fabry mouse model
(39,40). The lipid transport functions of saposin B could
be compensated by saposin C that also is involved in the
degradation of the LacCer (27). In fact, slight increases in
LacCer were detected in our newly generated saposin C
deﬁcient mice (Y. Sun et al., unpublished data). Such mouse
models demonstrate overlapping functions of saposins in
GSL metabolism in vivo.
B2/2 mice had progressive accumulation of multiple
GSLs, but predominantly sulfatide, in the CNS and PNS. In
the brain and spinal cord, sulfatide was detected in microglial
cells, oligodendrocytes and neuronal processes. A proinﬂam-
matory response was demonstrated by the presence of acti-
vated microglial cells or astrogliosis in tissues that
accumulated sulfatide. This suggests that the initiating event
for proinﬂammation in these tissues was the presence of
excess sulfatide. The oligodendrocytes were the major cell
types in B2/2 mice brains ﬁlled with storage materials
although no apparent changes were observed in myelin
sheets. Both NFA and HFA sulfatide accumulated in B2/2
mice. The ratio of NFA/HFA galactosylceramide has been
linked to developmental programming (41) and myelin stab-
ility (42). However, there was no effect of sulfatide accumu-
lation on myelin integrity in B2/2 mice. The normal
myelin structure in B2/2 mice could be due to maintenance
of unchanged NFA/HFA ratios despite an increase in total
sulfatide.
The neuronal inclusions were observed in both ASA
deﬁcient and B2/2 mice. In particular, storage inclusions
were found in their acoustic neurons. Neuronal storage of sul-
fatide has been reported to cause hyperexcitability and axonal
degeneration in mice (43). The acoustic startle response was
tested in the B2/2 mice, but neither WT nor B2/2 mice
showed adequate responses in the C57BL/6J strain. This is
due to the development of deafness in this stain of mice by
the age of testing. The C57BL/6J background strain is homo-
zygous for the age-related hearing loss mutation Cdh23
ahl that
causes progressive hearing loss with onset after 10 months of
age (JAX mice data base).
Saposin B participates in the degradation of sulfatide by
enhancing ASA activity (37). ASA null mice have slow
accumulation of sulfatide and develop CNS abnormalities
(33). The B2/2 mouse phenotype closely resembled this phe-
notype and biochemistry. Both models exhibit head tremor
caused by accumulation of sulfatide in CNS and normal
myelin ultrastructure. Like ASA null mice, B2/2 kidney
had remarkable sulfatide storage in the tubule epithelial cells
that was detectable as early as 7 weeks. Lung had only a
slight increase in sulfatide. Other visceral organs showed no
Figure 3. Phenotypes of saposin B2/2 mice. (A) Saposin B 2/2 mice exhibited hind-limb clasping during tail hanging by 15 months and (B) head tremor was
evident at 22 months. (C) Narrow bridges test. B2/2 mice were tested on 12 mm
2 square beam. The latency (left) and foot slips (right) in B2/2 became
progressively different from WT with increasing age. Male mice were used in the tests. WT, n ¼ 17; B2/2, n ¼ 26.  P , 0.01;   P , 0.001;    P ¼
0.0001 (Student’s t-test).
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compared with ASA deﬁcient mice was the accumulation of
LacCer and Gb3. In both mouse models, the disease is much
slower developing than the human analogues. Alternative sul-
fatide metabolism in mice may account for these differences
between humans and mice (44). Differences between mouse
models and the human diseases have been observed for
several lysosomal storage diseases, including acid
b-glucosidase knock-out mice (45), acid b-glucosidase
N370S mutant mice (38) and b-hexosaminidase A
(Tay-Sach disease) mice (46).
Saposins are essential lysosomal proteins in the GSLs
degradation pathway. The saposin B2/2 mouse model, as
well as those for other saposins (saposin A, D and CD),
should provide useful tools for investigating the pathogenesis
of sphingolipid storage diseases and for understanding how
saposins and their cognate enzymes interact and to maintain
the homeostasis of GSLs in the cell/tissues speciﬁc manner.
MATERIALS AND METHODS
Materials
The following were from commercial sources: NuPAGE 4–
12% Bis–Tris gel, NuPAGE MES SDS running buffer, mouse
anti-GFAPmonoclonalantibody,TopoTAcloningvector(Invi-
trogen,Carlsband,CA);Ratanti-mouseCD68monoclonalanti-
bodies (Serotec, Oxford, UK); M-PER (Mammalian Protein
Extraction Reagent) and BCA protein assay reagent (Pierce,
Rockford, IL). Molecular Dynamics Storm 860 scanner (GE
Figure 4. Long-term potentiation (LTP) analyses of saposin B2/2 hippocam-
pal regions: LTP was recorded as the slope of resulting EPSPs from the para-
sagittal sections (350 mm) of hippocampal CA1 region. The slopes of the
EPSP (LTP) were not signiﬁcantly different between 15-month-old B2/2
(black circles) and WT (open circles) male mice after recording for 90 min fol-
lowing stimulation. WT, n ¼ 6; B2/2, n ¼ 8.
Figure 5. Storage inclusions in neural tissues from B2/2 mice: H&E staining
of B2/2 mice neural tissue sections showed that the inclusion materials
(arrows) were present in neurons of spinal cord, brain stem, acoustic ganglion
of inner ear and dorsal root ganglion. WT mice did not show inclusions in
matched regions. The tissues sections were from 17-month-old WT and
B2/2 mice.
Figure 6. CD-68 and GFAP staining of CNS from B2/2 mice. (Upper panel) Activated microglial cells were present in the CNS of B2/2 mice. Microglial
cells staining with anti-CD68 antibody (brown) in (A) WT and (B)B 2/2 cerebella, (C)B 2/2 spinal cord and (D)B 2/2 brain stem. The sections were
counter stained with hematoxylin. (Lower panel) B2/2 mice showed increased anti-GFAP (green) antibody positive cells indicating astrogliosis in several
CNS regions. (E) WT and (F)B 2/2 thalami, (G)B 2/2 corpus colosum and (H)B 2/2 brain stem. The nuclei were stained with DAPI (blue). The
tissues sections were from 17-month-old mice.
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nitrocellulose membrane and ECL detection reagent
(Amersham Biosciences, Piscataway, NJ). Anti-fade/DAPI,
methyl green, ABC Vectastain and Alkaline phosphatase kit II
(Black) were used (Vector Laboratory, Burlingame, CA). DIG
Easy Hyb, Anti-digoxigenin-AP, CDP-Star, positively
charged nylon membrane and Lumi-ﬁlm chemiluminescent
detectionﬁlmwere used (Roche Applied Science, Indianapolis,
IN) as well as the Qiagen Quick-change II XL kit (Qiagen Inc.,
Valencia, CA). Restriction enzymes were from New England
BioLabs (Beverly, MA). TOTALLY RNA (Ambion Inc.,
Austin, TX) and High capacitycDNA archive kit (Applied Bio-
systems,FosterCity,CA)wasused.FITC-conjugatedgoatanti-
rabbit antibody and rhodamine-conjugated goat anti-rat anti-
body was used (ICN/CAPPEL, Aurora, OH), as was Alcian
blue (Poly Scientiﬁc, Bay Shore, NY).
Construction of the targeting vector and generation
of B2/2 mice
The mouse prosaposin genomic DNA clones and targeting
vector (OSdupdel) were kindly provided by Dr Kunihiko
Suzuki. A subclone 6-1 in pBluescript vector containing
exons 2-7 and subclone 4-1 with exons 4-7 was used to gener-
ate the saposin B targeting vector. Substitution of a conserved
cysteine (Cys) breaks one of the three disulﬁde bridges in the
selected saposin and results in the deﬁciency of that individual
saposin (14,21). This strategy was adapted to produce saposin
B deﬁciency by introducing a Cys!Phe substitution in
saposin B. This was accomplished using Qiagen Quick-change
II XL kit with mismatched oligonucleotide primers: B4F (50-T
GTC TCT CTG CAG TTT AAA AAC TAC GTG G-30), B4R
(50-CCA CGT GTT TTT AAA CTG CAG ACA GAC A-30)
using the subclone 4-1 as a template. The mismatched nucleo-
tides are underlined. The short arm BamHI - Kpn I 1.6 kb frag-
ment containing the saposin B mutation was generated by PCR
and subcloned into the TopoTA cloning vector. The long arm
Xho I-Cla I 4.0 kb fragments were generated by PCR using
subclone 6-1 as a template. The product was cloned into the
TA cloning vector. The saposin B targeting construct was
assembled in OSdupdel containing the Polymer enhancer/
herpes simplex virus thymidine kinase (MC1) promoter with
the neomycin (neo) gene ﬂanked by two loxP sites and the thy-
midine kinase (TK) gene driven by the 30 phosphoglycerate
kinase (PGK) promoter (23). The short arm (1.6 kb) contain-
ing the mutation was cloned into BamHI / Kpn I sites down-
stream of MC1-neo in the vector, thereby forming the 30
homologous region. The long arm (4.0 kb) released with
EcoR I from the TA cloning vector was blunt ligated into
Nhe I sites upstream of MC1-neo to form the 50 homologous
region. The sequences of long arm and short arm were vali-
dated by direct sequencing.
The targeting vector was linearized with Not1 and intro-
duced into the 129/SvEv ES cell line. Recombinant ES
Figure 7. Alcian blue (sulfatide) staining in CNS of B2/2 mice: (A) Alcian blue staining of B2/2 tissues showed sulfatide (blue) storage in: spinal cord (A),
kidney tubules (B), brain stem (E) and thalamus (F). WT spinal cord (C) and kidney (D) were free of alcian blue staining. (B) Consecutive spinal cord sections
from B2/2 mice were stained with alcian blue (A, C and E) and MBP (B), CD68 (D) and NeuN (F). (A and B) Alcian blue staining was localized to the MBP
positive region (star). (C and D) CD68 positive microglial cells contained alcian blue positive material (arrows). (E and F) Alcian blue staining was on a neuronal
process (arrow) and not in the neuronal soma. The tissues sections were from 15-month-old mice.
Human Molecular Genetics, 2008, Vol. 17, No. 15 2351clones were screened by PCR analysis using the primers inside
of the short arm: ABR1 (50-GCC AGA CCT GTC AGT TTG
TGA TGA A-30) or outside of the short arm: ABR2 (50-CTG
GAG GAG TTC TAT ACG TGC CCA-30), together with
the primer in the 30 region of neo, NEO30F2 (50-GGT GTT
GGG TCG TTT GTT CGG ATC A-30). The recombinant
and WT clones generated 1.4 and 1.6 kb PCR products,
respectively. The recombinant ES clones were conﬁrmed
with Southern blot analyses. The clones were digested by
BamHI / Bgl II and probed with the 50 probe. The muta-
tions in the recombinant clone were veriﬁed by PCR and
sequencing. The correctly targeted clones were used to gener-
ate chimeric mice by microinjection into C57BL/6J blasto-
cysts. Electroporation, ES cell culture, selection and chimera
breeding were carried out by the mouse Gene-targeting
service core at the University of Cincinnati. To remove the
neo gene, the heterozygous F1 mice were cross bred to
Zp3-Cre mice [C57BL/6-TgN(Zp3-Cre)93Knw; The Jackson
Laboratory]. The resulting females carrying the Zp3-Cre and
were saposin B deﬁciency heterozygotes (B+/-) were then
cross bred to Bþ/2 heterozygous males for Cre recombina-
tion between two loxP sites. Zp3-Cre transgene was out bred
by crosses of the Bþ/2; ZP3-Cre with WT C57BL/6J mice.
The intercross of Bþ/2 without neo and without Zp3-Cre gen-
erated the saposin B2/2 homozygotes. The strain of back-
ground for saposin B2/2 (B2/2) was C57BL/6J/129SvEv.
Figure 8. Ultrastructural kidney and CNS of saposin B2/2 mice. (A)A n
electron micrograph of a normal proximal renal tubular cell. Rare and non
speciﬁc small residual bodies were in the cytoplasm of the tubular lining
cell. (B) Proximal renal tubular epithelial cells contained numerous large
complex appearing multivesicular bodies (arrow). The storage materials con-
sisted of aggregates of variable size heterogeneous granular material with
slightly pale central cores surrounded by a rim of more electron dense amor-
phous material. (C) Renal epithelial cells from a distal tubule also contained a
large amount of storage material (arrow). The material was similar to that seen
in the proximal tubule in (B), although slightly less electron dense. A few of
the vesicular bodies contained layers of membranous material surrounding less
dense material in the central core. (D) An oligodendrocyte (arrow) in brain
stem next to a myelinated process. The oligodendrocyte contained storage
materials composed of dense membranous material surrounding more electron
lucent material. (E) A neuron from brain stem had a few scattered inclusion
bodies (arrows) representing storage materials. (F) A section through the
sciatic nerve with myelinated ﬁbers. The Schwann cells (arrows) contained
inclusion bodies including large vacuoles mixed with electron dense amor-
phous material. The tissues were from 15-month-old mice.
Figure 9. Glycosphingolipid analyses by TLC. (A) Lactosylceramide (LacCer,
asterisk) was slightly increased in B2/2 mice liver relative to WT, but lower
than LacCer level in PS2/2 mice (right panel). (B) Upper panel: Sulfatide
(arrowheads) accumulated in B2/2 kidney and was slightly elevated in
B2/2 lung. TriCer (arrows) was increased in B2/2 kidney. Bottom
panel: same plate as in the upper panel stained with Azure A to verify the sul-
fatide (arrowhead). (C) Gangliosides in B2/2 mice cortex were not changed
compared with WT cortex. WT and B2/2 samples were from 15-month-old
mice and PS2/2 is from 4-week-old mice.
2352 Human Molecular Genetics, 2008, Vol. 17, No. 15Prosaposin Knock-out (PS2/2) mice (23) were used in the
GSL analysis. The mice were maintained in microisolators
in accordance with institutional guidelines under IACUC
approval at Cincinnati Children’s Research Foundation.
PCR genotyping and Southern blot analyses
PCR reactions and Southern blotting were conducted as
described (34). The genotyping primers were B-F( 5 0-GAA
GGA AGC ATT TCA CCA GGC CAC T-30) and B-R
(50-GGA GTA ATG ACT AGT AGG GAG TGA TCA-30).
The PCR product from WT was 200 bp, and from B2/2
with neo was 1.4 kb and without neo was 307 bp. Using a 50
probe in Southern blotting, Bgl II/BamH I digestion generated
10.8 kb WT fragment and 6.8 kb recombinant fragment.
RT–PCR
Total RNA was extracted from mouse tissues using
TOTALLY RNA kit (Ambion Inc.). Reverse transcription of
total RNA (10 mg) for each tissue was carried out using the
High Capacity cDNA Archive Kit (Applied Biosystems) con-
taining random hexamers primers. The reaction was for
10 min at 258C and 120 min at 378C. The resulting cDNA
was ampliﬁed by PCR using the 10 pmol of primers PS-Left
(50-TGCAGCCTGCGAAGTGAAGC-30) and PSm-Reverse
Figure 10. ESI/MS analysis of sulfatide. (A) Kidney. (Upper panel) Non-hydroxy (NFA) sulfatide C20, C22, C24 and C24:1 accumulated in B2/2 mice com-
pared with control samples. (Lower panel) Hydroxyl (HFA) sulfatides C20–C24:1 were increased relative to WT. Kidney samples were from 48-week-old mice.
(B) Cortex and hippocampus. (Upper panel) NFA sulfatide C18, C24 and C24:1 were increased in B2/2 mice. (Lower panel) HFA sulfatide C18-C24:1 were at
higher levels than WT controls. Brain tissues were from 15-month-old mice. NFA sulfatide level was higher in cortex and hippocampus than kidney, whereas the
HFA sulfatide level was greater in the kidney than brain sections. The amount of sulfatide were normalized by mg protein (n ¼ 3).
Human Molecular Genetics, 2008, Vol. 17, No. 15 2353(50-TTCCACACATGGCGTTTG-30) to generate a 1.6 kb
product from prosaposin cDNA. A PCR reaction using
GAPDH (glyceraldehyde-3-phosphate dehydrogenase)
primers was the internal control. The PCR reaction of each
RNA sample without adding reverse transcriptase in RT reac-
tion was the negative control.
Histological analyses and immunoblotting
Tissues were collected after perfused with saline, ﬁxed in 10%
formalin, embedded in parafﬁn, sectioned to 4 mm and stained
with H&E. Karnovsky’s ﬁxative was used for ultrastructural
analyses. CD68 monoclonal antibody staining was with
paraformaldehyde-ﬁxed frozen sections as described (47).
For GFAP staining, paraformaldehyde-ﬁxed tissue sections
were blocked in 20% goat serum (GS), and incubated with
mouse anti-GFAP monoclonal antibody (Sigma, G3893) (1/
50 diluted in PBS with 20% GS). FITC-conjugated goat anti-
mouse antibody (1/100 in PBS) was added to the samples. The
samples were counter-stained with anti-fade/DAPI. The
signals were visualized with a Zeiss Axiovert 200M with an
Apotome. Alcian blue stain, which detects acidic sulfated
lipids, was used to demonstrate sulfatide accumulation in
tissues. Parafﬁn or frozen sections were rinsed in 3% acetic
acid for 3 min and stained with alcian blue solution, 1% in
acetic acid, pH 2.5 (Polyscientiﬁc, S111A) for 30 min. After
rinsing with 3% acetic acid followed by water, sections were
counterstained with Nuclear Fast Red. The parafﬁn sections
of spinal cords were incubated with Anti-MBP (1/100;
Sternberg mono Inc., SM199) and Anti-NeuN (1/100; Chemi-
con, MAB377), respectively. Visualization was with the ABC
Vectastain kit and Alkaline phosphatase kit II according to the
manufacturer(s) instructions.
GSL analyses
The GSLs in tissue samples (100 mg wet weight) were
extracted as described (47,48). Relative proportions of lipids
from the tissue samples were determined by TLC with
borate impregnated plates (10 cm
2 Merck HPTLC silica gel
60, 200 mm). Plates were developed in chloroform/methanol/
water (65:25:4, v/v/v). The gangliosides were resolve in
chloroform/methanol/0.22% CaCl2 (60:35:8, v/v/v). GSLs
were visualized with primulin spray (100 mg/l in 80%
acetone) and blue ﬂuorescence scanning (Storm 860, GE
Healthcare). Sulfatides were detected with Azure A spray
(2% in 1 mM H2S04) followed by destaining with 40 mM
H2S04/CH3OH (3:1, v/v) in water.
The levels of NFA and HFA sulfatide molecular species in
lipid extracts of tissue samples were determined by ESI/MS
using shotgun lipidomics for sphingolipid analysis (49,50).
Sulfatide contents were normalized to the protein content
within the same sample. Individual samples of cerebral
cortex, hippocampus and kidney from three B2/2 and
control (WT and Bþ/2) mice were separately analyzed.
Behavioral studies (narrow bridges)
The mice were tested on two different shapes of wood beams
during the training and test phases. Square beams (1 m) with
cross sections of 25, 12 and 5 mm
2, and round beams (1 m)
with diameters of 28, 17 and 11 mm were used. The horizontal
beams were 50 cm above the ﬂoor. Both ends of the beam
were mounted to narrow supports. The starting point of the
beam was illuminated with a 125 W ﬂoodlight and two
halogen lights. The end of the beam was attached to an
enclosed 20 cm
2 dark box. For the training phase, the mice tra-
versed the 12 mm
2 beam for three consecutive days, four trials
per day. The ﬁrst trial lasted a maximum of 2 min and each
subsequent trial was a maximum of 1 min. A successful
beam cross was recorded when an animal passed the second
support closest to the goal box. Animals were considered to
be trained when they crossed the 12 mm
2 beam in ,20 s. If
a mouse failed to traverse the beam on the ﬁrst day, then on
the second day the mouse was allowed to start trials in the
middle of the beam. Once the mouse successively traversed
the beam, the start position was then moved back to the orig-
inal start position. The test phase began on the fourth day and
each mouse in turn received two consecutive trials (up to 60 s/
trial) on each square and round beam in a progression from
widest to narrowest. Latency to traverse each beam and the
number of times the hind feet slipped off the beam were
recorded. A total of 26 B2/2 male and 17 age-matched
WT male mice were included in the test. The tests were
started when mice were 2-month-old and repeated at 12 and
15 month.
Tail hanging reﬂex observations
Mice were lifted by tail to observe the legs reﬂex. The legs of
normal mice were in ‘V’ position. The affected mice exhibited
inward trend with legs and a clasped position.
Locomotor activity
Individual male mice (26 B2/2 and 17 WT) were placed in
activity chambers for 60 min. Locomotor activity was
measured in a 41   41   30 cm Accuscan activity monitor
equipped with 16 pairs of photodetector-LED beams along
the x and y axes (Accuscan Electronics with VersaMax soft-
ware, Columbus, OH). The apparatus was cleaned with 70%
ethanol between animals. Horizontal activity was recorded in
5 min intervals. B2/2 and WT mice were alternated
between each chamber in the test to minimize time of day
effects. The test was conducted under normal ﬂuorescent
light conditions. The mice were tested at 2, 12 and 15 month.
Electrophysiology
Electrophysiology was performed using the MED64 multi-
electrode array system (Alpha Med Sciences, Kadoma,
Japan) (51). Fifteen-month-old mice (8 B2/2 male and
6 WT male) were decapitated and the brains were placed in
cold artiﬁcial cerebral spinal ﬂuid (aCSF: 124 mM NaCl,
26 mM NaHCO3,1 0 m M dextrose 3 mM KCl, 1.25 mM
NaH2PO4,2m M CaCl2 and 1 mM MgSO4). Parasagittal sec-
tions (350 mm) were taken from the hippocampus and trans-
ferred to a warm (348C) oxygenated aCSF bath for 1 h. A
section was placed in the recording chamber on an 8   8 elec-
trode array with the hippocampus oriented so that the CA1
2354 Human Molecular Genetics, 2008, Vol. 17, No. 15region was on the array to determine LTP in the Schaffer col-
lateral pathway. The recording chamber was perfused with
warm (378C) aCSF at a rate of 0.5 ml/min and a humidiﬁed
oxygen (95%)/CO2 (5%) mix was added to the chamber at a
rate of 2 ml/min. Pair-pulse stimuli were delivered at CA1
and excitatory post-synaptic potentials (EPSPs) were recorded
until stable baseline slopes were achieved for a minimum of
10 min. Following baseline recording, a theta burst stimulation
(5 Hz for 2 s) was applied to the section. The slope of resulting
EPSPs was recorded for 90 min following stimulation. Brain
sections were recorded in duplicate for each animal and the
data were averaged per animal. Data were analyzed using Per-
former 2.0 software (Alpha Med Sciences).
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